Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Average PT from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.33.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th.

Amylyx Pharmaceuticals Stock Down 2.3 %

Shares of AMLX opened at $3.43 on Monday. The company has a market capitalization of $303.90 million, a price-to-earnings ratio of -0.90 and a beta of -0.53. Amylyx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $7.27. The stock has a 50 day moving average price of $3.55 and a 200 day moving average price of $4.07.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. On average, equities analysts anticipate that Amylyx Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the completion of the transaction, the chief executive officer now owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This represents a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Frates sold 10,896 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $37,809.12. Following the completion of the sale, the chief financial officer now directly owns 290,988 shares of the company’s stock, valued at approximately $1,009,728.36. This trade represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,509 shares of company stock valued at $222,586 over the last ninety days. Corporate insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. FMR LLC grew its position in Amylyx Pharmaceuticals by 292.0% during the third quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after buying an additional 164,622 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after acquiring an additional 83,048 shares in the last quarter. Barclays PLC grew its holdings in shares of Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock worth $274,000 after acquiring an additional 40,319 shares during the period. Walleye Capital LLC increased its stake in Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after purchasing an additional 608,874 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Amylyx Pharmaceuticals by 17.5% during the third quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock worth $1,786,000 after purchasing an additional 82,173 shares during the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.